German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

15 Years to 65 Years (Child, Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

T-lymphoblastic lymphoma (bone marrow [BM] involvement < 25%)

Aged 15-65 years (55-65 years if biologically younger)

Written informed consent

Exclusion Criteria:

Severe complications due to lymphoma or secondary disease

T-LBL as second malignancy or other active second malignancy

Cytostatic pretreatment of LBL (exception of emergency treatments)

Pregnancy

Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent